NDLI: Murine infection models for vaccine development: the malaria example.

Please wait, while we are loading the content...

Mucosal and systemic antibody responses to potential Pseudomonas aeruginosa vaccine protein antigens in young children with cystic fibrosis following colonization and infection.

The study of novel DNA vaccines against tuberculosis: Induction of pathogen-specific CTL in the mouse and monkey models of tuberculosis

Novel therapeutic vaccines [(HSP65 + IL-12)DNA-, granulysin- and Ksp37-vaccine] against tuberculosis and synergistic effects in the combination with chemotherapy

Applications and challenges of multivalent recombinant vaccines.

Murine infection models for vaccine development: the malaria example.

Immunising with the transmembrane envelope proteins of different retroviruses including HIV-1: a comparative study.

Potential impact of the bivalent rLP2806 vaccine on Neisseria meningitidis carriage and invasive serogroup B disease.

Capsular polysaccharides are an important immune evasion mechanism for Staphylococcus aureus.

Immunogenicity in mice and non-human primates of the Group A Streptococcal J8 peptide vaccine candidate conjugated to CRM197

Identification and characterization of antigens as vaccine candidates against Klebsiella pneumoniae.

Carriage of Streptoccoccus pneumoniae in healthy adults aged 60 years or over in a population with very high and long-lasting pneumococcal conjugate vaccine coverage in children: rationale and perspectives for PCV13 implementation.

Are vaccination models suitable to determine whether probiotics have beneficial health effects in the general population?

Epitope-specific immune recognition of the nontypeable Haemophilus influenzae outer membrane protein 26.

Progress in the elimination of measles and congenital rubella in Central Italy.

Influenza epidemiology in Italy two years after the 2009–2010 pandemic: Need to improve vaccination coverage

Cross-protection against drifted influenza viruses: options offered by adjuvanted and intradermal vaccines.

Head-to-head comparison of an intradermal and a virosome influenza vaccine in patients over the age of 60: evaluation of immunogenicity, cross-protection, safety and tolerability.

Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy.

Economic benefits of inactivated influenza vaccines in the prevention of seasonal influenza in children.

Are risk factors associated with invasive pneumococcal disease according to different serotypes?

Immunotherapy in new pre-clinical models of HPV-associated oral cancers

A plant-produced H1N1 trimeric hemagglutinin protects mice from a lethal influenza virus challenge

Epidemiology of HBV S-gene mutants in the Liguria Region, Italy: Implications for surveillance and detection of new escape variants.

Neisseria lactamica antigens complexed with a novel cationic adjuvant.

Results of the rubella elimination program in Catalonia (Spain), 2002-2011.

Surveillance of influenza viruses in the post-pandemic era (2010-2012) in Northern Italy.

Surveillance of hospitalized and outpatient cases of pertussis in Catalonia from 2003 to 2009.

Epidemiology of two large measles virus outbreaks in Catalonia: what a difference the month of administration of the first dose of vaccine makes.

Epidemiology of vaccine-preventable invasive diseases in Catalonia in the era of conjugate vaccines.

Relevance of a pre-existing measles immunity prior immunization with a recombinant measles virus vector.

Effectiveness of the WC/rBS oral cholera vaccine in the prevention of traveler's diarrhea: a prospective cohort study.

A plant-produced protective antigen vaccine confers protection in rabbits against a lethal aerosolized challenge with Bacillus anthracis Ames spores.

Sequence and immunogenicity of a clinically approved novel measles virus vaccine vector.

Sero-epidemiology of hepatitis B markers in the population of Tuscany, Central Italy, 20 years after the implementation of universal vaccination.

Influenza sentinel surveillance network: a public health-primary care collaborative action to assess influenza A(H1N1)pmd09 in Catalonia, Spain.

Eighth World Congress on Vaccines, Immunisation and Immunotherapy.

Letter from the editor.

Year: 2013 Volume: 9 Issue: 2

Year: 2013 Volume: 9 Issue: 1

Year: 2012 Volume: 8

Murine infection models for vaccine development: the malaria example.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Matuschewski, Kai
Description	Country affiliation: Germany Author Affiliation: Matuschewski K ( Parasitology Unit)
Abstract	Vaccines are developed and eventually licensed following consecutive human clinical trials. Malaria is a potential fatal vector-borne infectious disease caused by blood infection of the single-cell eukaryote Plasmodium. Pathogen stage conversion is a hallmark of parasites in general and permits unprecedented vaccine strategies. In the case of malaria, experimental human challenge infections with Plasmodium falciparum sporozoites can be performed under rigorous clinical supervision. This rare opportunity in vaccinology has permitted many small-scale phase II anti-malaria vaccine studies using experimental homologous challenge infections. Demonstration of safety and lasting sterile protection are central endpoints to advance a candidate malaria vaccine approach to phase II field trials. A growing list of antigens as targets for subunit development makes pre-selection and prioritization of vaccine candidates in murine infection models increasingly important. Preclinical assessment in challenge studies with murine Plasmodium species also led to the development of whole organism vaccine approaches. They include live attenuated, metabolically active parasites that educate effector memory T cells to recognize and inactivate developing parasites inside host cells. Here, opportunities from integrating challenge experiments with murine Plasmodium parasites into malaria vaccine development will be discussed.
File Format	HTM / HTML
ISSN	21645515
e-ISSN	2164554X
Journal	Human Vaccines & Immunotherapeutics
Issue Number	3
Volume Number	9
Language	English
Publisher	Taylor & Francis
Publisher Date	2013-03-01
Publisher Place	United States
Access Restriction	Open
Subject Keyword	Discipline Immunology Discipline Therapeutics Disease Models, Animal Drug Discovery Malaria Vaccines Immunology Isolation & Purification Malaria, Falciparum Prevention & Control Plasmodium Falciparum Physiology Animals Mice Research Support, Non-u.s. Gov't
Content Type	Text
Resource Type	Article
Subject	Immunology and Allergy Immunology Pharmacology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Tuberculosis vaccine development: Shifting focus amid increasing development challenges.

Current advances and challenges in the development of Acinetobacter vaccines.

Development of Toxoplasma gondii vaccine: A global challenge.

Malaria vaccine can prevent millions of deaths in the world.

Malaria invasion ligand RH5 and its prime candidacy in blood-stage malaria vaccine design.

Hepatitis C vaccine. Need of the hour.

Challenges of assessing the clinical efficacy of asexual blood-stage Plasmodium falciparum malaria vaccines.

Still hope for schistosomiasis vaccine.

A novel recombinant vaccine protecting mice against abrin intoxication.

Murine infection models for vaccine development: the malaria example.

Similar Documents

Tuberculosis vaccine development: Shifting focus amid increasing development challenges.

Current advances and challenges in the development of Acinetobacter vaccines.

Development of Toxoplasma gondii vaccine: A global challenge.

Malaria vaccine can prevent millions of deaths in the world.

Malaria invasion ligand RH5 and its prime candidacy in blood-stage malaria vaccine design.

Hepatitis C vaccine. Need of the hour.

Challenges of assessing the clinical efficacy of asexual blood-stage Plasmodium falciparum malaria vaccines.

Still hope for schistosomiasis vaccine.

A novel recombinant vaccine protecting mice against abrin intoxication.

Murine infection models for vaccine development: the malaria example.